Market Place
News Type
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
X
Developments Infections and Infectious Diseases Phase I
Japan 
Details:
DS-5670, an mRNA vaccine, being evaluated against the novel coronavirus infectious disease (COVID-19). DS-5670 induced a neutralizing activity against previously designated Variant of Concerns, including the Delta variant.
Lead Product(s): mRNA Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: DS-5670
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 21, 2021
Details:
DS-2319 contains nafamostat mesilate that has been formulated in an inhalation dosage form. It is being studied for treating COVID-19 since it has been shown to block membrane fusion between the viral envelope that causes COVID-19 and the host plasma cell membrane.
Lead Product(s): Nafamostat
Therapeutic Area: Infections and Infectious Diseases Product Name: DS-2319
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 30, 2021
Details:
The first volunteer was injected with the inactivated virus vaccine known as KD-414, the company said in a release. The study is a combined Phase 1 and Phase 2 trial involving 210 subjects to test the vaccine’s safety and ability to trigger an immune response.
Lead Product(s): KD-414
Therapeutic Area: Infections and Infectious Diseases Product Name: KD-414
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2021
